foxo4-dri senolytic human trial The costs and benefits of senotherapeutics for health FOXO4-DRI alleviates age-related testosterone secretion
FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOX04 DRI (10mg) Nordsci FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
Pay in 4 interest-free payments of $5.16 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




